Health Benefits of Correcting Vitamin D Deficiency
The 2024 Endocrine Society Clinical Practice Guideline provides the most current framework for who benefits from vitamin D optimization. The evidence is strongest in the following areas:
Respiratory Infections — An individual participant data meta-analysis of 25 RCTs (n = 10,933) found vitamin D supplementation reduced acute respiratory infections overall (aOR 0.88, 95% CI 0.81–0.96). The benefit was dramatically stronger in those with severe deficiency (25(OH)D < 25 nmol/L): aOR 0.30 (95% CI 0.17–0.53), representing a 70% risk reduction. Daily or weekly dosing was effective, while intermittent bolus dosing was not. However, a 2025 updated meta-analysis of 46 RCTs (n = 64,086) found the overall protective effect was no longer statistically significant (OR 0.94, 95% CI 0.88–1.00), suggesting earlier estimates may have been inflated.
Cancer Mortality — While vitamin D does not reduce cancer incidence, multiple RCTs and meta-analyses consistently show a reduction in cancer mortality. A systematic review of 107 RCTs found suggestive evidence for benefit specifically on cancer death rates. A separate meta-analysis confirmed that 10–20 μg/day of vitamin D can reduce both all-cause and cancer mortality in middle-aged and older adults.
Type 2 Diabetes Prevention — In adults with prediabetes, moderate-certainty evidence from the D2d trial and meta-analyses suggests vitamin D supplementation reduces progression to type 2 diabetes.
Autoimmune Disease — The VITAL trial's ancillary autoimmune study found vitamin D 2,000 IU/day reduced the incidence of autoimmune disease by 22% over 5 years. An international consensus statement supports vitamin D optimization for immune tolerance, particularly in documented deficiency.
Bone Health — Vitamin D at 700–800 IU/day reduces hip fractures by ~25% in older adults, while 400 IU/day shows no benefit — a clear dose-response relationship. However, this benefit is primarily demonstrated in institutionalized or vitamin D-deficient elderly, not community-dwelling adults with adequate levels.
All-Cause Mortality — A systematic review supporting the Endocrine Society guideline found a very small but statistically significant reduction in mortality among adults older than 75 years with high certainty of evidence.
- *Key Caveats and Nuance
The critical distinction in the vitamin D literature is between deficient and replete populations. The large VITAL (n = 25,871), ViDA, and D2d trials showed that supplementing vitamin D-replete adults (baseline 25(OH)D > 50 nmol/L) does not prevent cancer, cardiovascular events, falls, or diabetes progression. The Endocrine Society guideline explicitly recommends against routine supplementation beyond the RDA in healthy adults aged 19–74 years, reserving targeted supplementation for high-risk groups.